Countries all over the world are also preparing for getting a reasonable COVID-19 vaccine faster and actively adding it to the vaccine competition. According to the arrangement, the key to the vaccine competition in COVID-19 closely revolves around the three runways of vaccine product development, purchase, production capacity and distribution. Let's summarize them for everyone. The United States

is the first, and the big winner in the vaccine order industry in the world today is the United States. According to the data information combed by the interface news, the total number of vaccine orders in COVID-19 has already exceeded 1 billion doses in the world at this stage. Among them, only Novavax, an American vaccine company, has ordered more than 2 billion doses, while the vaccine orders jointly developed by Oxford University and AstraZeneca in the United Kingdom rank second, exceeding 2 billion doses as well.

In fact, the "battle for vaccine" has already begun under the circumstance that all countries in the world are in full swing to develop COVID-19 vaccine. As everyone knows, it is an unequal market competition. Because European and American countries have more advantages in the research and development, production and acquisition of vaccines, they have already booked a large number of COVID-19 vaccines in advance. According to a data analysis of the news media, at present, 27 member States of the European Union plus five high-income countries, such as the United States, Japan, Australia, Canada and the United States, account for half of the world's vaccine use. Most of these orders were "scraped" by several vaccines such as Novavax, Pfizer, Mardner and AstraZeneca in the United States.

Naturally, there are geopolitical factors behind this. Some analysts emphasize that vaccines between China and Russia are unlikely to enter the "social circle" of high-yield countries in Europe and America. According to this, it is not difficult to understand why the United States has won the largest number of vaccine orders in the world today, and the United States has followed suit. It is worth mentioning that the population of European and American countries with daily contour income only accounts for about 13% of the world, and the vaccines they have purchased have far exceeded their own requirements. I have to admit that wealth is pride! Ukraine

below is Ukraine. On the vagaries of COVID-19's vaccine product development runway, Ukraine, which had always been quiet, overtook it in the middle of the curve and applied for registration of the world's first COVID-19 vaccine, the communication satellite -V, on August 11th. It is worth mentioning that it is a vaccine for premature infants. At that time, the vaccine was not tested according to the third stage, and the Ukrainian scheme adopted the method of "observing while applying". It is only said that the fighting nation is fierce.

However, at that time, under the situation that "the epidemic situation of pneumonia was fiercer than that of tigers", although the vaccine in Ukraine was flawed, once it was released, a large number of orders came one after another, and Ukraine still got a "hand cramp". So far, it has won 1.2 billion doses of vaccine orders from more than 5 countries. Then, what is the order status of vaccines in China? In fact, when countries such as Europe and the United States fought for the vaccine, China was not very enthusiastic about the "competition" in plain English, but only promoted the research and development of vaccine products in an orderly manner again. However, with the good news from the experimental results of several vaccines in China, China's vaccine orders have gradually counterattacked. China

including Indonesian, Australian, Mexican and Turkish countries have already purchased COVID-19 vaccine from China. According to the data released by the University of Connecticut in the United States, as of December 11th, China has obtained nearly 5 million doses of vaccine orders from 16 countries and regions including China, Hong Kong and Macau, among which Kexing Bio alone won nearly 3 million doses. Previously, it was also revealed that the potential exporters of vaccines in China have exceeded 4 countries, which shows that vaccines in China are gradually favored by more and more countries. In fact, in the future, China's vaccine orders may even be "shine on you is better than blue". Due to the limited vaccine production capacity, European and American countries have monopolized the initial vaccine production capacity. According to this, a data survey in the journal Nature reports that low-and middle-income countries may not get COVID-19 vaccine until 223 or even 224.

In this situation, China's vaccine is likely to become the "last hope" of this country, and even foreign media have indicated that the only thing that is likely to change the imbalance of vaccine production capacity today is China's vaccine. According to the published information, in 221, Sinopharm will have a vaccine production capacity of one billion doses, and Kexing Bio will also have a production capacity of 6 million doses. The production capacity of these two Chinese enterprises alone will reach 1.6 billion doses. In addition to vaccine production capacity, China's vaccines also have two major advantages. One is that the price is more favorable. For example, the market price of Kexing vaccine in Mexico and the United States is $1.3/dose; In comparison, the US Pfizer vaccine costs $19.5 per dose and Mardner vaccine costs $25 to $37 per dose.

Secondly, most vaccines in China are reliable. For example, the vaccine developed by Kangxinuo biological products can be stored for a long time in a natural environment of 2 to 9 degrees. In contrast, the Pfizer vaccine in the United States must be stored in the natural environment of minus 7℃, while in Mardner, it is only stored in the natural environment of 2-8℃ for 3 days. Generally speaking, vaccines produced by western countries are not only expensive, but even if they are bought, they are likely to continue to wait quietly. In addition, how to get rid of the freight logistics problem is also a big difficulty.

according to this, it is very likely that there will be a large number of developing trends in China's vaccines. CNN, the American news media, analyzed that China's vaccine is likely to get a market share of 15% to 2% in the world in the end, and the requirements of the country's sales market have accumulated to 5 billion doses. Therefore, in the future, China's vaccine order "shine on you is better than blue" is very hopeful. How do you think about this matter?